THC, CBD and Dementia Agitation: Simply Explained
Published: Presented at the Alzheimer's Association International Conference, London, July 14, 2026
Researchers: Jacobo Mintzer MD (Medical University of South Carolina / Georgetown University) — the LiBBY Trial, NIH-funded, 10 medical centres
1. What Was Studied?
Agitation is one of the most distressing symptoms in late-stage dementia — it causes restlessness, aggression, and emotional distress that affects both patients and their caregivers. Current medications for it are limited and often carry significant side effects.
This Phase II clinical trial, called the LiBBY trial, enrolled 120 people with Alzheimer's disease or other forms of dementia who were hospice-eligible and experiencing clinically significant agitation. Participants were randomly assigned to receive either a placebo or an oral THC and CBD formulation twice daily for 12 weeks — conducted across 10 medical centres, with visits taking place in participants' own homes.
2. What Did They Find?
After just two weeks, those receiving THC and CBD had agitation scores 6.27 points lower on average than the placebo group — a rapid and significant improvement
By week 12, 87.2% of the treatment group showed overall behavioral improvement, compared with 23.6% receiving placebo
Adverse event rates were similar between the two groups — meaning the treatment did not cause meaningfully more side effects than placebo
The lead investigator described it as a level of response "not seen before in clinical trials related to dementia"
The study was funded by the National Institutes of Health and the Alzheimer's Association
3. What This Means
This is one of the most significant cannabis studies of 2026 — not just for what it found, but for who it was about. People in the final stages of dementia are among the most vulnerable and least-studied populations in medical research. Existing medications for agitation in this group often provide limited relief while carrying serious risks.
The fact that nearly 90% of participants responded — compared to fewer than 25% on placebo — is an unusually large gap for any clinical trial, and researchers said so explicitly. The home-based design also means the results reflect how this population actually lives, not a controlled hospital setting.
4. What This Does NOT Mean
This was a Phase II trial — larger Phase III trials are needed before any clinical recommendations can be made
The specific formulation used (2mg THC / 100mg CBD twice daily in a rapid-acting oil) is not currently available as a consumer product
Results apply specifically to late-stage dementia with agitation — not dementia broadly, and not other conditions
THC-containing products carry considerations for older adults around balance, cognitive effects, and medication interactions
Families should speak with a geriatric specialist before considering any cannabinoid product for a loved one with dementia
5. Bottom Line
A Phase II trial found that a THC and CBD combination reduced agitation in nearly 90% of late-stage dementia patients — a response rate researchers called unprecedented for this condition, though larger trials are still needed.
🗣️ Mary Jane's Take
This one is personal for a lot of families. Late-stage dementia agitation is one of the most heartbreaking things to watch, and current options are genuinely limited. These results are striking — 87% response versus 24% on placebo is not a small signal. It's early, but it matters.
